• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Sight Sciences Appoints Gary Burbach to its Board of Directors

    4/22/25 4:05:00 PM ET
    $BWXT
    $SGHT
    Industrial Machinery/Components
    Industrials
    Medical/Dental Instruments
    Health Care
    Get the next $BWXT alert in real time by email

    MENLO PARK, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) (Sight Sciences, or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today that Gerhard (Gary) F. Burbach was appointed to the Company's Board of Directors on April 21, 2025. Mr. Burbach will serve as a Class II director with a term expiring at the 2026 Annual Meeting of Stockholders.

    "We are very excited to add Gary to our Board of Directors," stated Paul Badawi, Co-founder and Chief Executive Officer of Sight Sciences. "He brings a strong medtech industry background with a proven track record of success in commercial and operational leadership at multiple private and public medical device companies. Gary's prior experience as CEO leading the growth of Thoratec Corporation, a company that pioneered the development of mechanical circulatory assist devices for the heart and created a new standard of care in the treatment of advanced heart failure, is particularly relevant to Sight Sciences. As we focus on maintaining our leadership position in the surgical glaucoma segment and executing on our strategy to achieve equitable market access in our dry eye segment, Gary's substantial market development and growth expertise will be invaluable to our executive team and our Board of Directors. We look forward to his strategic insights and guidance as we continue our mission to build a leading interventional eye care business."

    Mr. Burbach added, "I am thrilled to join the Board of Directors of Sight Sciences at this pivotal time as both glaucoma and dry eye, two of the largest markets in eye care, are poised for a transformation towards interventional care and represent significant growth and market development opportunities. I look forward to collaborating with this top-tier executive team and Board to help the Company achieve its full potential."

    Mr. Burbach is a member of the Board of Directors and Chair of the Compensation Committee of BWX Technologies (NYSE:BWXT), a publicly-traded company that provides innovative nuclear technology solutions including medical isotopes and radiopharmaceuticals, and Chairman of the Board of Directors of Procyrion Inc., a private medical device company focused on the treatment of chronic heart failure. He previously served as a member of the Board of Directors of Fluidigm Corporation (now Standard Bio Tools (NAS: LAB)), a public company manufacturing and marketing innovative technologies for life sciences research, from 2013 to 2023, as Chairman of the Board of Directors of Artelon, Inc., a private company specializing in biomaterial development for tendon and ligament reconstruction, from 2020 until its acquisition by Stryker Corporation in 2024, and as a member of the Board of Directors of Vascular Dynamics, Inc., a private medical device company that developed innovative solutions for heart failure and hypertension, from 2017 to 2024. From 2006 to 2014, Mr. Burbach was President, Chief Executive Officer and a member of the Board of Directors of Thoratec Corporation, manufacturer of proprietary medical devices for circulatory support that was acquired by St. Jude Medical, Inc. (now Abbott Laboratories). Prior to that, he held executive leadership positions at Digirad Corporation, Philips Medical Systems, and ADAC Laboratories. Mr. Burbach also spent six years at McKinsey & Company, Inc., focused primarily on the firm's healthcare practice. Mr. Burbach holds a Bachelor of Science in Industrial Engineering from Stanford University and a Master of Business Administration from Harvard Business School.

    About Sight Sciences

    Sight Sciences is an eyecare technology company focused on developing and commercializing innovative and interventional solutions intended to transform care and improve patients' lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world's most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company's OMNI® Surgical System is an implant-free glaucoma surgery technology (i) indicated in the United States to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and (ii) CE Marked for the catheterization and transluminal viscodilation of Schlemm's canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma. Glaucoma is the world's leading cause of irreversible blindness. The SION® Surgical Instrument is a bladeless, manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The Company's TearCare® System is 510(k) cleared in the United States for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland disease (MGD), enabling clearance of gland obstructions by physicians to address the leading cause of dry eye disease. Visit www.sightsciences.com for more information.

    Sight Sciences, the Sight Sciences logo, TearCare, SmartHub and SmartLids are trademarks of Sight Sciences registered in the United States. OMNI and SION are trademarks of Sight Sciences registered in the United States, European Union and other territories.

    © 2025 Sight Sciences. All rights reserved.

    Forward-Looking Statements

    This press release, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which statements are subject to considerable risks and uncertainties. The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and includes this statement for purposes of complying with these safe harbor provisions. Any statements made in this press release that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements and should be evaluated as such. Forward-looking statements include all statements other than statements of historical fact, including statements concerning the Company's focus on maintaining its leadership position in the surgical glaucoma segment and executing on its strategy to achieve equitable market access in the dry eye segment, the Company's ability to build a leading interventional eye care business, the Company's growth and market development opportunities, and the expectations and perceived benefits of the appointment of Gerhard F. Burbach to the Company's Board of Directors. These statements often include words such as "anticipate," "expect," "suggests," "plan," "believe," "intend," "estimates," "targets," "projects," "should," "could," "would," "may," "will," "forecast" and other similar expressions. We base these forward-looking statements on our current expectations, plans and assumptions that we have made in light of our experience in the industry, as well as our perceptions of historical trends, current conditions, expected future developments and other factors we believe are appropriate under the circumstances at such time. Although management believes these forward-looking statements are based upon reasonable assumptions at the time they are made, management cannot guarantee their accuracy or completeness. Forward-looking statements are subject to and involve risks, uncertainties and assumptions that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance, or achievements predicted, assumed or implied by such forward-looking statements. Some of the risks and uncertainties that may cause actual results to materially differ from those expressed or implied by these forward-looking statements are discussed under the caption "Risk Factors" in the Company's filings with the SEC, as may be updated from time to time in subsequent filings. These cautionary statements should not be construed by you to be exhaustive and are made only as of the date of this press release. Sight Sciences undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

    Media contact:

    [email protected]

    Investor contact:

    Philip Taylor

    Gilmartin Group

    415.937.5406

    [email protected]



    Primary Logo

    Get the next $BWXT alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $BWXT
    $SGHT

    CompanyDatePrice TargetRatingAnalyst
    BWX Technologies Inc.
    $BWXT
    7/8/2025$150.00Buy → Hold
    Deutsche Bank
    BWX Technologies Inc.
    $BWXT
    5/28/2025Outperform
    William Blair
    BWX Technologies Inc.
    $BWXT
    4/1/2025$145.00Buy
    Seaport Research Partners
    Sight Sciences Inc.
    $SGHT
    12/6/2024$5.50Buy
    UBS
    BWX Technologies Inc.
    $BWXT
    11/12/2024$148.00Neutral → Overweight
    Alembic Global Advisors
    Sight Sciences Inc.
    $SGHT
    11/4/2024$10.00 → $5.00Buy → Hold
    Lake Street
    Sight Sciences Inc.
    $SGHT
    8/21/2024$10.00Buy
    Lake Street
    BWX Technologies Inc.
    $BWXT
    7/24/2024$75.00 → $90.00Equal Weight → Underweight
    Barclays
    More analyst ratings

    $BWXT
    $SGHT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BWX Technologies downgraded by Deutsche Bank with a new price target

      Deutsche Bank downgraded BWX Technologies from Buy to Hold and set a new price target of $150.00

      7/8/25 8:27:25 AM ET
      $BWXT
      Industrial Machinery/Components
      Industrials
    • William Blair initiated coverage on BWX Technologies

      William Blair initiated coverage of BWX Technologies with a rating of Outperform

      5/28/25 9:07:05 AM ET
      $BWXT
      Industrial Machinery/Components
      Industrials
    • Seaport Research Partners initiated coverage on BWX Technologies with a new price target

      Seaport Research Partners initiated coverage of BWX Technologies with a rating of Buy and set a new price target of $145.00

      4/1/25 7:36:37 AM ET
      $BWXT
      Industrial Machinery/Components
      Industrials

    $BWXT
    $SGHT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Technology Officer Badawi David exercised 40,000 shares at a strike of $0.12, increasing direct ownership by 2% to 1,871,025 units (SEC Form 4)

      4 - Sight Sciences, Inc. (0001531177) (Issuer)

      7/18/25 6:36:35 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Pres., Government Operations Miller Joseph Kirwan

      4 - BWX Technologies, Inc. (0001486957) (Issuer)

      7/8/25 4:25:19 PM ET
      $BWXT
      Industrial Machinery/Components
      Industrials
    • New insider Miller Joseph Kirwan claimed ownership of 3,870 shares (SEC Form 3)

      3 - BWX Technologies, Inc. (0001486957) (Issuer)

      7/8/25 4:24:05 PM ET
      $BWXT
      Industrial Machinery/Components
      Industrials

    $BWXT
    $SGHT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Project Pele Begins Taking Shape with Start of Core Manufacturing

      BWX Technologies, Inc. (NYSE:BWXT) announced today that work has commenced to fabricate the reactor core for the Pele microreactor at its BWXT Innovation Campus in Lynchburg, Virginia. Pele is a 1.5-megawatt demonstration microreactor for the Department of Defense Strategic Capabilities Office. The technology is expected to begin producing electricity in 2028. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250724939919/en/Production platform for the Pele prototype core reactor assembly. The Pele microreactor is gas-cooled and designed to be transportable. The reactor and its associated systems fit into four 20-foot-long shipping

      7/24/25 4:30:00 PM ET
      $BWXT
      Industrial Machinery/Components
      Industrials
    • Sight Sciences to Report Second Quarter 2025 Financial Results on August 7, 2025

      MENLO PARK, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, today announced it will report financial results for the second quarter ended June 30, 2025, after the market close on Thursday, August 7, 2025. The Company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.sightscienc

      7/24/25 4:05:00 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • BWXT Fires Up Furnace for Advanced Nuclear Fuel

      BWX Technologies, Inc. (NYSE:BWXT) announced today that it reached a key milestone in its capability to manufacture an advanced form of TRISO nuclear fuel, representing the next generation of fuel for advanced reactors. TRISO fuel comprises carbon and silicon layers surrounding a uranium fuel kernel. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250722984355/en/The chemical vapor infiltration furnace at BWXT's Lynchburg Technology Center in Lynchburg, Virginia. The furnace is manufactured by AVS, Incorporated. Source: BWXT The company's Advanced Technologies subsidiary recently completed the installation and testing of a chemic

      7/22/25 8:00:00 AM ET
      $BWXT
      Industrial Machinery/Components
      Industrials

    $BWXT
    $SGHT
    SEC Filings

    See more

    $BWXT
    $SGHT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • BWX Technologies Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - BWX Technologies, Inc. (0001486957) (Filer)

      6/16/25 7:41:12 AM ET
      $BWXT
      Industrial Machinery/Components
      Industrials
    • SEC Form 8-K filed by Sight Sciences Inc.

      8-K - Sight Sciences, Inc. (0001531177) (Filer)

      6/5/25 4:46:57 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • SEC Form SD filed by Sight Sciences Inc.

      SD - Sight Sciences, Inc. (0001531177) (Filer)

      5/30/25 4:35:00 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • Director Encrantz Staffan bought $381,958 worth of shares (90,525 units at $4.22) and was granted 30,952 shares, increasing direct ownership by 10% to 1,377,964 units (SEC Form 4)

      4 - Sight Sciences, Inc. (0001531177) (Issuer)

      6/6/25 9:10:58 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • Director Encrantz Staffan bought $376,429 worth of shares (98,782 units at $3.81), increasing direct ownership by 9% to 1,256,487 units (SEC Form 4)

      4 - Sight Sciences, Inc. (0001531177) (Issuer)

      6/3/25 9:57:16 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • Director Encrantz Staffan bought $451,734 worth of shares (128,189 units at $3.52), increasing direct ownership by 12% to 1,157,705 units (SEC Form 4)

      4 - Sight Sciences, Inc. (0001531177) (Issuer)

      5/29/25 9:31:17 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care

    $BWXT
    $SGHT
    Leadership Updates

    Live Leadership Updates

    See more
    • BWXT Announces Leadership Changes

      BWX Technologies, Inc. (NYSE:BWXT) announced today the appointment of Kevin M. McCoy as the company's chief nuclear officer. In this role, McCoy will support the Department of Defense and Department of the Navy to accelerate the pace of Columbia and Virginia Class submarine production programs for the U.S. Navy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250616718800/en/BWXT today announced the following leadership changes: Kevin McCoy to Chief Nuclear Officer; Joe Miller to president of Government Operations; and Kate Kelly to president, Advanced Technologies. Since 2022, McCoy has served as president of BWXT's Government O

      6/16/25 7:30:00 AM ET
      $BWXT
      Industrial Machinery/Components
      Industrials
    • Sight Sciences Appoints Gary Burbach to its Board of Directors

      MENLO PARK, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) (Sight Sciences, or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today that Gerhard (Gary) F. Burbach was appointed to the Company's Board of Directors on April 21, 2025. Mr. Burbach will serve as a Class II director with a term expiring at the 2026 Annual Meeting of Stockholders. "We are very excited to add Gary to our Board of Directors," stated Paul Badawi, Co-founder and Chief Executive Officer of Sight Sciences. "He brings a strong medtech industry background with a pro

      4/22/25 4:05:00 PM ET
      $BWXT
      $SGHT
      Industrial Machinery/Components
      Industrials
      Medical/Dental Instruments
      Health Care
    • BWXT Joint Venture Awarded Strategic Petroleum Reserve Contract

      BWX Technologies, Inc. (NYSE:BWXT) announced today a U.S. Department of Energy award to manage and operate the Strategic Petroleum Reserve. Strategic Storage Partners, LLC was formed by lead parent company APTIM Federal Services and BWXT Technical Services Group, Inc. to safely manage and operate the structures and systems of the Strategic Petroleum Reserve. The estimated value of the contract is approximately $2.6 billion over 10 years, comprising a five-year base period and one five-year option. The scope of the contract includes operating and maintaining the Strategic Petroleum Reserve's facilities and related systems, maintaining the highest levels of quality control, developing and i

      4/9/25 4:15:00 PM ET
      $BWXT
      Industrial Machinery/Components
      Industrials

    $BWXT
    $SGHT
    Financials

    Live finance-specific insights

    See more
    • Sight Sciences to Report Second Quarter 2025 Financial Results on August 7, 2025

      MENLO PARK, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, today announced it will report financial results for the second quarter ended June 30, 2025, after the market close on Thursday, August 7, 2025. The Company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.sightscienc

      7/24/25 4:05:00 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • BWX Technologies to Announce Second Quarter 2025 Results on Monday, August 4

      BWX Technologies, Inc. (NYSE:BWXT) will issue a news release detailing second quarter 2025 results on Monday, August 4, 2025, after market close and will host a conference call at 5:00 p.m. EDT. Listen-only participants are encouraged to participate and view the supporting presentation via the internet at investors.bwxt.com. The dial-in numbers for participants are (U.S.) 1-888-596-4144 and (International) 1-646-968-2525; conference ID: 3934110. A replay of the call will remain available on the BWXT website for a limited time. About BWXT At BWX Technologies, Inc. (NYSE:BWXT), we are People Strong, Innovation Driven. A U.S.-based company, BWXT is a Fortune 1000 and Defense News Top 100

      7/1/25 4:15:00 PM ET
      $BWXT
      Industrial Machinery/Components
      Industrials
    • Sight Sciences Reports First Quarter 2025 Financial Results and Reaffirms Full Year 2025 Revenue Guidance

      MENLO PARK, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today reported financial results for the first quarter ended March 31, 2025, reaffirms revenue guidance for full year 2025, and announces improved adjusted operating expenses guidance for full year 2025.   Recent Financial and Business Highlights Generated first quarter 2025 total revenue of $17.5 million, a decrease of 9% compared to the same period in the prior year. This decline was primarily due to lower revenue from the Company's

      5/8/25 4:05:00 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care

    $BWXT
    $SGHT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Sight Sciences Inc.

      SC 13G/A - Sight Sciences, Inc. (0001531177) (Subject)

      11/14/24 11:57:36 AM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by BWX Technologies Inc.

      SC 13G/A - BWX Technologies, Inc. (0001486957) (Subject)

      11/14/24 10:58:08 AM ET
      $BWXT
      Industrial Machinery/Components
      Industrials
    • Amendment: SEC Form SC 13G/A filed by BWX Technologies Inc.

      SC 13G/A - BWX Technologies, Inc. (0001486957) (Subject)

      11/8/24 10:34:33 AM ET
      $BWXT
      Industrial Machinery/Components
      Industrials